Curis FY2025 EPS Estimate Increased by Cantor Fitzgerald

Curis, Inc. (NASDAQ:CRIS) – Research analysts at Cantor Fitzgerald upped their FY2025 earnings estimates for Curis in a report issued on Wednesday, April 30th. Cantor Fitzgerald analyst L. Watsek now expects that the biotechnology company will post earnings of ($1.52) per share for the year, up from their previous forecast of ($2.34). The consensus estimate for Curis’ current full-year earnings is ($7.12) per share.

A number of other equities analysts have also recently issued reports on CRIS. HC Wainwright dropped their price objective on Curis from $20.00 to $16.00 and set a “buy” rating for the company in a report on Monday, March 31st. StockNews.com started coverage on shares of Curis in a report on Wednesday. They issued a “hold” rating on the stock.

Curis Stock Performance

CRIS opened at $2.41 on Friday. The stock’s 50 day moving average price is $2.09 and its 200-day moving average price is $3.19. Curis has a one year low of $1.02 and a one year high of $16.93. The stock has a market cap of $20.46 million, a price-to-earnings ratio of -0.31 and a beta of 3.51.

Curis (NASDAQ:CRIS) last issued its quarterly earnings results on Monday, March 31st. The biotechnology company reported ($1.25) EPS for the quarter, beating the consensus estimate of ($1.36) by $0.11. The company had revenue of $2.70 million for the quarter, compared to the consensus estimate of $2.04 million. Curis had a negative net margin of 443.35% and a negative return on equity of 923.37%.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CRIS. Wealthquest Corp bought a new position in shares of Curis during the 1st quarter worth $1,542,000. M28 Capital Management LP lifted its stake in Curis by 23.5% in the fourth quarter. M28 Capital Management LP now owns 521,059 shares of the biotechnology company’s stock worth $1,594,000 after acquiring an additional 99,108 shares during the period. Bleichroeder LP grew its holdings in Curis by 1,982.2% during the 4th quarter. Bleichroeder LP now owns 520,539 shares of the biotechnology company’s stock worth $1,593,000 after acquiring an additional 495,540 shares in the last quarter. CM Management LLC increased its position in Curis by 83.3% during the 4th quarter. CM Management LLC now owns 220,000 shares of the biotechnology company’s stock valued at $673,000 after purchasing an additional 100,000 shares during the period. Finally, Alyeska Investment Group L.P. purchased a new stake in shares of Curis in the 4th quarter worth approximately $607,000. 29.97% of the stock is currently owned by hedge funds and other institutional investors.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.